losartan has been researched along with Heart Diseases in 14 studies
Losartan: An antagonist of ANGIOTENSIN TYPE 1 RECEPTOR with antihypertensive activity due to the reduced pressor effect of ANGIOTENSIN II.
losartan : A biphenylyltetrazole where a 1,1'-biphenyl group is attached at the 5-position and has an additional trisubstituted imidazol-1-ylmethyl group at the 4'-position
Heart Diseases: Pathological conditions involving the HEART including its structural and functional abnormalities.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The use of losartan with sodium valproate in epilepsy may prevent the cognitive and cardiac sequelae of seizures." | 7.91 | Effects of enalapril and losartan alone and in combination with sodium valproate on seizures, memory, and cardiac changes in rats. ( Arava, S; Gupta, YK; Joshi, D; Katyal, J, 2019) |
| "The use of losartan with sodium valproate in epilepsy may prevent the cognitive and cardiac sequelae of seizures." | 3.91 | Effects of enalapril and losartan alone and in combination with sodium valproate on seizures, memory, and cardiac changes in rats. ( Arava, S; Gupta, YK; Joshi, D; Katyal, J, 2019) |
| "Angiotensin II (Ang II) and aldosterone contribute to hypertension, oxidative stress and cardiovascular damage, but the contributions of aldosterone during Ang II-dependent hypertension are not well defined because of the difficulty to assess each independently." | 3.81 | Angiotensin and mineralocorticoid receptor antagonism attenuates cardiac oxidative stress in angiotensin II-infused rats. ( Conte, D; Minas, JN; Nishiyama, A; Ortiz, RM; Thorwald, MA; Vázquez-Medina, JP, 2015) |
| "Nandrolone decanoate treatment increased the QTc interval and reduced the parasympathetic indexes of HRV (RMSSD, pNN5 and high-frequency power) in sedentary and trained rats." | 1.39 | The blockade of angiotensin AT1 and aldosterone receptors protects rats from synthetic androgen-induced cardiac autonomic dysfunction. ( da H Silva, A; dos Santos, MC; Ferraz, EF; Marques Neto, SR; Nascimento, JH, 2013) |
| "Myocardial fibrosis increases arrhythmia vulnerability of the diseased heart." | 1.36 | Reduction of fibrosis-related arrhythmias by chronic renin-angiotensin-aldosterone system inhibitors in an aged mouse model. ( Boulaksil, M; de Bakker, JM; Engelen, MA; Hauer, RN; Herold, E; Houtman, MJ; Jansen, JA; Joles, JA; Noorman, M; Stein, M; van Rijen, HV; van Veen, TA, 2010) |
| "Hypertension is strongly associated with increased risk of subsequent heart failure." | 1.35 | [Hypertension and the heart]. ( Andersen, NH; Svendsen, TL; Wachtell, K, 2009) |
| "Aldosterone plays a key role in the pathogenesis of Ang II-induced organ damage." | 1.33 | Aldosterone synthase inhibitor ameliorates angiotensin II-induced organ damage. ( Al-Saadi, N; Dechend, R; Fiebeler, A; Hilfenhaus, G; Jeng, AY; Luft, FC; Maser-Gluth, C; Meiners, S; Muller, DN; Nussberger, J; Rong, S; Shagdarsuren, E; Webb, RL; Wellner, M, 2005) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 3 (21.43) | 18.2507 |
| 2000's | 4 (28.57) | 29.6817 |
| 2010's | 6 (42.86) | 24.3611 |
| 2020's | 1 (7.14) | 2.80 |
| Authors | Studies |
|---|---|
| Gonzalez, EA | 1 |
| Tobar Leitão, SA | 1 |
| Soares, DDS | 1 |
| Tavares, AMV | 1 |
| Giugliani, R | 1 |
| Baldo, G | 1 |
| Matte, U | 1 |
| Joshi, D | 1 |
| Katyal, J | 1 |
| Arava, S | 1 |
| Gupta, YK | 1 |
| Matouk, AI | 1 |
| Taye, A | 1 |
| Heeba, GH | 1 |
| El-Moselhy, MA | 1 |
| Minas, JN | 1 |
| Thorwald, MA | 1 |
| Conte, D | 1 |
| Vázquez-Medina, JP | 1 |
| Nishiyama, A | 1 |
| Ortiz, RM | 1 |
| Osborn, MJ | 1 |
| Webber, BR | 1 |
| McElmurry, RT | 1 |
| Rudser, KD | 1 |
| DeFeo, AP | 1 |
| Muradian, M | 1 |
| Petryk, A | 1 |
| Hallgrimsson, B | 1 |
| Blazar, BR | 1 |
| Tolar, J | 1 |
| Braunlin, EA | 1 |
| Wachtell, K | 1 |
| Andersen, NH | 1 |
| Svendsen, TL | 1 |
| Stein, M | 1 |
| Boulaksil, M | 1 |
| Jansen, JA | 1 |
| Herold, E | 1 |
| Noorman, M | 1 |
| Joles, JA | 1 |
| van Veen, TA | 1 |
| Houtman, MJ | 1 |
| Engelen, MA | 1 |
| Hauer, RN | 1 |
| de Bakker, JM | 1 |
| van Rijen, HV | 1 |
| Marques Neto, SR | 1 |
| da H Silva, A | 1 |
| dos Santos, MC | 1 |
| Ferraz, EF | 1 |
| Nascimento, JH | 1 |
| Fiebeler, A | 1 |
| Nussberger, J | 1 |
| Shagdarsuren, E | 1 |
| Rong, S | 1 |
| Hilfenhaus, G | 1 |
| Al-Saadi, N | 1 |
| Dechend, R | 1 |
| Wellner, M | 1 |
| Meiners, S | 1 |
| Maser-Gluth, C | 1 |
| Jeng, AY | 1 |
| Webb, RL | 1 |
| Luft, FC | 1 |
| Muller, DN | 1 |
| Baumgart, P | 1 |
| Karasek, D | 1 |
| Adamski, M | 1 |
| Grzeszczak, W | 1 |
| Symons, JD | 1 |
| Stebbins, CL | 1 |
| Musch, TI | 1 |
| Coca, A | 1 |
| Giner, V | 1 |
| Pinto, YM | 1 |
| Pinto-Sietsma, SJ | 1 |
| Philipp, T | 1 |
| Engler, S | 1 |
| Kossamehl, P | 1 |
| Hocher, B | 1 |
| Marquardt, H | 1 |
| Sethmann, S | 1 |
| Lauster, R | 1 |
| Merker, HJ | 1 |
| Paul, M | 1 |
2 reviews available for losartan and Heart Diseases
| Article | Year |
|---|---|
[Antagonists of angiotensin II receptor].
Topics: Angiotensin Receptor Antagonists; Biphenyl Compounds; Heart Diseases; Humans; Hypertension; Imidazol | 1996 |
[Antihypertensive advantages of angiotensin II AT1 receptor antagonism].
Topics: Aged; Angiotensin II; Angiotensin Receptor Antagonists; Anti-Arrhythmia Agents; Antihypertensive Age | 1999 |
12 other studies available for losartan and Heart Diseases
| Article | Year |
|---|---|
Cardiac pathology in mucopolysaccharidosis I mice: Losartan modifies ERK1/2 activation during cardiac remodeling.
Topics: Animals; Disease Models, Animal; Echocardiography; Female; Heart Diseases; Iduronidase; Losartan; Ma | 2021 |
Effects of enalapril and losartan alone and in combination with sodium valproate on seizures, memory, and cardiac changes in rats.
Topics: Animals; Anticonvulsants; Drug Therapy, Combination; Enalapril; Heart Diseases; Kindling, Neurologic | 2019 |
Quercetin augments the protective effect of losartan against chronic doxorubicin cardiotoxicity in rats.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Anti-Inflammatory Agents; Antioxidants; Biomarkers | 2013 |
Angiotensin and mineralocorticoid receptor antagonism attenuates cardiac oxidative stress in angiotensin II-infused rats.
Topics: Adrenal Glands; Aldehydes; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Biomark | 2015 |
Angiotensin receptor blockade mediated amelioration of mucopolysaccharidosis type I cardiac and craniofacial pathology.
Topics: Angiotensin Receptor Antagonists; Animals; Craniofacial Abnormalities; Disease Models, Animal; Femal | 2017 |
[Hypertension and the heart].
Topics: Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Atrial Fibrillation; Cardiovascula | 2009 |
Reduction of fibrosis-related arrhythmias by chronic renin-angiotensin-aldosterone system inhibitors in an aged mouse model.
Topics: Age Factors; Aging; Angiotensin II Type 1 Receptor Blockers; Animals; Arrhythmias, Cardiac; Blood Pr | 2010 |
The blockade of angiotensin AT1 and aldosterone receptors protects rats from synthetic androgen-induced cardiac autonomic dysfunction.
Topics: Anabolic Agents; Angiotensin II Type 1 Receptor Blockers; Animals; Heart Diseases; Losartan; Male; M | 2013 |
Aldosterone synthase inhibitor ameliorates angiotensin II-induced organ damage.
Topics: Adrenal Glands; Adrenalectomy; Aldosterone; Angiotensin II; Angiotensinogen; Animals; Animals, Genet | 2005 |
[Antihypertensive therapy: risk stratification in diabetes and cardiac diseases].
Topics: Adrenergic beta-Antagonists; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme | 2006 |
Interactions between angiotensin II and nitric oxide during exercise in normal and heart failure rats.
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Animals; Blood Pressure; Female; Heart Diseases; H | 1999 |
Reduction in left ventricular messenger RNA for transforming growth factor beta(1) attenuates left ventricular fibrosis and improves survival without lowering blood pressure in the hypertensive TGR(mRen2)27 Rat.
Topics: Animals; Cardiomegaly; Disease Models, Animal; Fibrosis; Heart Diseases; Heart Ventricles; Hypertens | 2000 |